Gastroesophageal Reflux Clinical Trial
Official title:
Effects of Diet and Alcohol on Fullness, Reflux and Dyspeptic Symptoms After Meals
Reflux and dyspeptic symptoms are common affecting 10-20% of the population on a regular
basis. Reflux symptoms such as heartburn and regurgitation are caused by the return of acid
or non-acid gastric contents into the esophagus. Dyspeptic symptoms are caused by abnormal
gastric relaxation (impaired accommodation) or increased sensitivity of the stomach to
distension during the meal.
The effects of diet on gastrointestinal function are debated and the efficacy of dietary
management for digestive symptoms has not been established. Epidemiological studies suggest
an effect; however, it is not possible to distinguish the effects of fat intake and total
energy (i.e. calorie) intake in this work. This issue has been addressed by small
physiological studies. The results show that esophageal acid exposure was related to total
calorie intake but not to fat content. In contrast, the number of reflux symptoms was 40%
higher after the high-fat than the low-fat meals. Similar findings were found for the
relationship between gastric distension, fullness and dyspeptic symptoms by Magnetic
Resonance Imaging. Thus, it appears that fat does not cause digestive dysmotility but
heightens sensitivity to visceral events and so increases the number and severity of
symptoms reported by patients. As yet, these findings have not been confirmed in larger,
more representative surveys.
Similar to the effects of food, there are inconsistent findings regarding the effects of
alcohol on gastro-esophageal reflux (GER) and gastric function. Physiological studies have
noted delayed gastric emptying and an increase in reflux events when alcohol is taken with
food. However, larger surveys have not confirmed that alcohol triggers reflux or dyspeptic
symptoms.
The proposed observational, dietary study with cross-over design will assess the independent
effects of energy intake (i.e. calorie load) and fat intake on gastric fullness, the number
and severity of reflux and dyspeptic symptoms after meals. The effect of alcohol on symptoms
after the high calorie, high fat meals will also be documented. The study population of
senior academics attending a conference are likely to have a relatively high prevalence of
risk factors for gastro-esophageal reflux disease (GERD) being predominantly male, with an
older age and a larger waist circumference than average in the general community. This will
increase study power and relevance of the findings.
The results will provide new information concerning the impact of dietary factors and
alcohol on digestive symptoms after meals. This data will inform future guidelines for the
dietary management of patients with reflux and dyspeptic symptoms after meals which will be
relevant in both primary and secondary care.
This is an observational, dietary study with cross-over design. Restaurant style meals and
beverages are provided to faculty and delegates attending the Ascona II conference that
agree to participate and provide written consent. Approximately 120 participants are
expected to be recruited.
On four consecutive days the evening meal served will vary in calorie load and fat content
using the established, partially balanced study design applied in previous studies. On the
first three days fruit juice will be served, whereas, on the final day, an alcoholic
beverage with the same acidity and number of calories will be served. All meals will have
the same size and salt content. Controlling for all these parameters will reduce possible
confounding factors in the analysis.
1. High calorie (1200 kcal), High fat (50% energy), 400 ml juice (230 kcal)
2. High calorie (1200 kcal), Low fat (20% energy), 400 ml juice (230 kcal)
3. Low calorie (600 kcal), Low fat (20% energy), 400 ml juice (230 kcal)
4. High calorie (1200 kcal), High fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal),
100 ml water Note: The order of meals on day 1-3 will be fixed, but not necessarily in
the order above. Meal constituents will not be disguised.
Note: Testing digestive symptoms in response to diet on successive days is possible because
clinical physiological studies have shown no evidence of a sequence effect in previous
studies using similar test meals.
An alginate-antacid preparation will be available as required for acute relief of any reflux
or dyspeptic symptoms (Gaviscon Liquid, Reckitt Benckiser (available across-the-counter for
this indication in Switzerland)). No participant is required to take this preparation.
The occurrence and severity of fullness, reflux and dyspeptic symptoms will be recorded
contemporaneously by participants for three hours after each of the four test meals using a
mobile application (SymTrack, Gastric Imaging & Analysis GmbH, Zürich, Switzerland). Paper
forms will be made available for those without a mobile device. Three hours is the period of
time during which reflux and dyspeptic symptoms are most often reported after meals.
Positive reporting bias will be minimized by automatic reminders sent to the participants by
the SymTrack every 30 minutes for three hours to remind participants to document the
severity of symptoms including, if appropriate, an absence of symptoms. The use of the
rescue medication to treat reflux and dyspeptic symptoms during the study will also be
documented on the SymTrack. Symptoms and use of the rescue medication that occur after this
three hour period up to 12 hours (i.e. the following morning) will be documented as part of
safety follow-up data; however these will not contribute to primary or secondary outcomes.
All faculty and delegates will be invited to participate in this observational, dietary
study. The investigators expect to recruit all, or nearly all, of those attending. The fixed
menu provided every night by the restaurant will be the same whether the attendee does or
does not participate in the study (unless specific dietary requirements are present).
Involvement of almost all attendees will reduce selection bias; however, selection bias will
remain because the group of clinical academics is not wholly representative of the general
population. Note that the study population is predominantly male, with an older age and a
larger waist circumference than the average in the community. These are all risk factors for
reflux disease. This should increase study power to show treatment effect and the clinical
relevance of findings.
All those attending the Centro Stefano Franscini conference centre in Ascona take their
evening meal together. The cost of these meals is included in the registration package. This
is a fixed menu with non-alcoholic drinks (alcohol is available to purchase). No other food
is available on site except for individuals that have registered special dietary
requirements. If other food is wanted, then this is available nearby in the town of Ascona.
This local organizational arrangement with the provision of fixed meals free of charge will
encourage compliance with the diet.
If the participants do not adhere to the meal and beverages set out in the study protocol
then this can be documented using the SymTrack. To assess compliance, the participant will
respond to the questions "did the patient consume the study meal?", "did the patient take
additional food?", "did the patient consume the study beverage?", and "did the patient take
additional alcoholic drinks?". Failure to comply with study procedures will not preclude the
individual from participating on the following days.
The primary study analysis will investigate associations between number symptoms and caloric
and fat content of the meals. It will be expressed as odds ratio. There will be a
qualitative description of the deviation from study protocol. For example if participants
report drinking alcohol during or after the meal on days 1-3 this will be expressed as a
percentage deviation.
The primary and secondary variables plus other outcomes of interest will be documented using
a mobile application (SymTrack; Gastric Imaging and Analysis GmbH, Zürich, Switzerland).
Paper symptom diaries will be available for those participants without access to a
smartphone.
On arrival at the meeting each attendee that agrees to participate and signs Written
Informed Consent will be given personal instructions as to the operation of the mobile
application. Should any difficulties remain then investigators, including those involved in
the development of the app, will be on hand to assist participants.
Once the Written Informed Consent is signed the participants will be given a unique username
and password to allow them to log into the SymTrack and start entering screening information
and symptoms. This username will allow the identification of study participant as data is
entered and ensure effective monitoring of data.
The primary analysis will be performed following study completion. The primary outcome is
the number of reflux or dyspeptic symptoms. Odds ratio will be computed to describe the
association of the number of symptoms with the meal calorie load and fat content.
Secondary outcomes are the severity of reflux and the severity of dyspeptic symptoms as well
as sensation of fullness after each test meal. Analogue to the primary outcome an odds ratio
will be computed to describe the association of these outcomes with the meal calorie load
and fat content.
An odds ratio will be computed to describe the association of the primary and secondary
outcomes with the ingestion of alcohol after the meal.
An additional analysis will be performed to identify factors - other than composition of the
test meal - that increase the likelihood of reporting reflux and dyspeptic symptoms after
meals (e.g. age, gender, BMI and low quality of life score).
Control questions that describe the study compliance will be described using descriptive
statistics.
The majority of data acquired in this study originates from electronic sources. Screening
data and symptoms entered via the smartphone are immediately transferred over an encrypted
channel to the server and stored in a MySQL-database. Both the server application and the
database are hosted on a professional application hosting provider located in Switzerland.
The server application and the database design are developed and tested by Gastric Imaging &
Analysis GmbH. The software version used during this study will be tested using
semi-automated functional tests and load tests. Study principal investigator (Mark Fox) is
responsible for all data stored in the database.
To ensure that the study is conducted in accordance with ethical principles, internal
monitoring will be carried out regularly throughout the study. At the screening the internal
monitor will review the protocol, and the database and all other aspects of the study with
the investigator and other staff. Monitoring will be carried out early in the study and
again after the last subject has completed the study. During monitoring, the monitor will
verify compliance with the protocol and amendment(s), review the signed informed consent
forms, diverse logs and all other source data. Direct access to all study-related site and
source data/documents is mandatory for the monitoring review. Study team staff must be made
available to answer any queries during the monitoring process.
;
Observational Model: Case-Crossover, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561179 -
Hyaluronic Acid in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01946971 -
Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01825473 -
Study of Erythromycin in GER-Associated Apnea of the Newborn
|
N/A | |
Completed |
NCT00614536 -
Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period
|
Phase 4 | |
Completed |
NCT00365300 -
Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)
|
Phase 3 | |
Completed |
NCT00284908 -
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00373997 -
Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux
|
Phase 4 | |
Completed |
NCT00215787 -
Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
|
N/A | |
Completed |
NCT00567021 -
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
|
N/A | |
Completed |
NCT00141960 -
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
|
Phase 2/Phase 3 | |
Completed |
NCT00226044 -
Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants.
|
Phase 3 | |
Completed |
NCT01167543 -
Relationship and Pathophysiology of Gastroesophageal Reflux and Dental/Periodontal Disease
|
N/A | |
Completed |
NCT00291746 -
Validation of RDQ Questionnaire
|
Phase 4 | |
Completed |
NCT01048840 -
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
|
||
Completed |
NCT00181805 -
Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents
|
||
Terminated |
NCT01281553 -
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
|
Phase 4 | |
Completed |
NCT05486169 -
Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy
|
N/A | |
Completed |
NCT04034017 -
Gastroesophageal Reflux Disease Among College Students
|
||
Terminated |
NCT03226054 -
Determining Risk Factors for Successful PPI Weaning
|
N/A |